Drug-induced uveitis

Journal of Ophthalmic Inflammation and Infection

Volumn 3, Issue 1, 2013, Pages 1-18

  London, Nikolas J S ^a   Garg, Sunir J ^b   Moorthy, Ramana S ^c,d   Cunningham Jr , Emmett T ^e,f  

^a San Diego CA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c ST VINCENT HOSPITAL   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAXOLOL; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BRIMONIDINE; CHICKENPOX VACCINE; CHOLINESTERASE INHIBITOR; CIDOFOVIR; DIETHYLCARBAMAZINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GLUCOCORTICOID; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; METIPRANOLOL; ORAL CONTRACEPTIVE AGENT; PROSTAGLANDIN DERIVATIVE; QUINIDINE; QUINOLONE DERIVATIVE; RANIBIZUMAB; RESERPINE; RIFABUTIN; SILDENAFIL; SMALLPOX VACCINE; SULFONAMIDE; TOPIRAMATE; TRIAMCINOLONE ACETONIDE; TRIFLUOPERAZINE; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

CHICKENPOX; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; HEPATITIS B; HUMAN; INFLUENZA; PRIORITY JOURNAL; REVIEW; UVEITIS;

EID: 84886584984     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1186/1869-5760-3-43     Document Type: Review

References (215)

1. Moorthy RS, Valluri S, Jampol LM (1998) Drug-induced uveitis. Surv Ophthalmol 42:557-570
2. Cunningham ET Jr, Pasadhika S, Suhler EB, Zierhut M (2012) Drug-induced inflammation in patients on TNFα inhibitors. Ocul Immunol Inflamm 20:2-5
3. Cunningham ET Jr, Zierhut M (2010) TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm 18:421-423
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245
5. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, Jaffe HS (1995) (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 171:788-796
6. Lalezari JP (1997) Cidofovir: a new therapy for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 14(Suppl 1):S22-S26
7. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ (1992) Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 41:197-202
8. Chavez-de la Paz E, Arevalo JF, Kirsch LS, Munguia D, Rahhal FM, De Clercq E, Freeman WR (1997) Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology 104:539-544
9. Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R, Freeman WR (1995) Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 119:466-476
10. Tseng AL, Mortimer CB, Salit IE (1999) Iritis associated with intravenous cidofovir. Ann Pharmacother 33:167-171
11. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE (1997) Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 115:733-737
12. Akler ME, Johnson DW, Burman WJ, Johnson SC (1998) Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology 105:651-657
13. Ambati J, Wynne KB, Angerame MC, Robinson MR (1999) Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol 83:1153-1158
14. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (2000) Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC peripheral cytomegalovirus retinitis trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. AIDS 14:1571-1581
15. Scott RA, Pavesio C (2000) Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection. Am J Ophthalmol 130:126-127
16. Lopez V, Sola E, Gutierrez C, Burgos D, Cabello M, Garcia I, Florez P, Lopez J, Gonzalez-Molina M (2006) Anterior uveitis associated with treatment with intravenous cidofovir in kidney transplant patients with BK virus nephropathy. Transplant Proc 38:2412-2413
17. Rahhal FM, Arevalo JF, Munguia D, Taskintuna I, Chavez de la Paz E, Azen SP, Freeman WR (1996) Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 103:1078-1083
18. Smith WM, Reddy MG, Hutcheson KA, Bishop RJ, Sen HN (2012) Rifabutinassociated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect 2:149-152
19. Skolik S, Willermain F, Caspers LE (2005) Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm 13:483-485
20. Saran BR, Maguire AM, Nichols C, Frank I, Hertle RW, Brucker AJ, Goldman S, Brown M, Van Uitert B (1994) Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 112:1159-1165
21. Shafran SD, Deschenes J, Miller M, Phillips P, Toma E (1994) Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC study group of the Canadian HIV trials network. N Engl J Med 330:438-439
22. Siegal FP, Eilbott D, Burger H, Gehan K, Davidson B, Kaell AT, Weiser B (1990) Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS 4:433-441
23. Frank MO, Graham MB, Wispelway B (1994) Rifabutin and uveitis. N Engl J Med 330:868
24. Shafran SD, Singer J, Zarowny DP, Deschenes J, Phillips P, Turgeon F, Aoki FY, Toma E, Miller M, Duperval R, Lemieux C, Schlech WF 3rd (1998) Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 177:252-255
25. Skinner MH, Blaschke TF (1995) Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 28:115-125
26. Kuper JI, D'Aprile M (2000) Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 39:203-214
27. Cato A 3rd, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R (1998) The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 63:414-421
28. Jacobs DS, Piliero PJ, Kuperwaser MG, Smith JA, Harris SD, Flanigan TP, Goldberg JH, Ives DV (1994) Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 118:716-722
29. Schimkat M, Althaus C, Becker K, Sundmacher R (1996) Rifabutin-associated anterior uveitis in patients infected with human immunodeficiency virus. Ger J Ophthalmol 5:195-201
30. Watts NB (2003) Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 19:395-414
31. Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135:219-222
32. Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220-224
33. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J (2003) Ocular sideeffects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 19:371-375
34. De S, Meyer P, Crisp AJ (1995) Pamidronate and uveitis. Br J Rheumatol 34:479
35. Stewart GO, Stuckey BG, Ward LC, Prince RL, Gutteridge DH, Constable IJ (1996) Iritis following intravenous pamidronate. Aust N Z J Med 26:414-415
36. Ghose K, Waterworth R, Trolove P, Highton J (1994) Uveitis associated with pamidronate. Aust N Z J Med 24:320
37. O'Donnell NP, Rao GP, Aguis-Fernandez A (1995) Paget's disease: ocular complications of disodium pamidronate treatment. Br J Clin Pract 49:272-273
38. Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348:1187-1188
39. Malik AR, Campbell SH, Toma NM (2002) Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 86:1443
40. Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117:837-838
41. Salmen S, Berrueta L, Sanchez N, Montes H, Borges L (2002) Nongranulomatous anterior uveitis associated with alendronate therapy. Invest Clin 43:49-52
42. Siris ES (1993) Bisphosphonates and iritis. Lancet 341:436-437
43. Tan YL, Sims J, Chee SP (2009) Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica 223:215-216
44. Fraunfelder FW, Fraunfelder FT (2004) Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 111:1275-1279
45. Moore MM, Beith JM (2008) Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust 188:370-371
46. Banal F, Briot K, Ayoub G, Dougados M, Roux C (2008) Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. J Rheumatol 35:2458-2459
47. Benderson D, Karakunnel J, Kathuria S, Badros A (2006) Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma 7:145-147
48. Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC (2008) Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 359:1410-1411
49. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
50. Fietta P, Manganelli P, Lodigiani L (2003) Clodronate induced uveitis. Ann Rheum Dis 62:378
51. Tilden ME, Rosenbaum JT, Fraunfelder FT (1991) Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol 109:67-69
52. Northrop CV, Shepherd SM, Abbuhl S (1996) Sulfonamide-induced iritis. Am J Emerg Med 14:577-579
53. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS (1995) Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 102:1669-1676
54. Arola O, Peltonen R, Rossi T (1998) Arthritis, uveitis, and Stevens-Johnson syndrome induced by trimethoprim. Lancet 351:1102
55. Pathak S, Power B (2007) Bilateral acute anterior uveitis as a side effect of trimethoprim. Eye (Lond) 21:252-253
56. Kristinsson JK, Hannesson OB, Sveinsson O, Thorleifsson H (1997) Bilateral anterior uveitis and retinal haemorrhages after administration of trimethoprim. Acta Ophthalmol Scand 75:314-315
57. Gilroy N, Gottlieb T, Spring P, Peiris O (1997) Trimethoprim-induced aseptic meningitis and uveitis. Lancet 350:112
58. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147
59. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187-1193
60. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
61. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842-1847
62. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903-912
63. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D (2004) Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111:352-356
64. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, Rebello P, Waldmann H, Hale G, Forrester JV, Dick AD (2004) Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 122:845-851
65. Okada AA, Goto H, Ohno S, Mochizuki M (2012) Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 130:592-598
66. Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA (2010) Autoimmune diseases induced by biological agents: a doubleedged sword? Autoimmun Rev 9:188-193
67. Kakkassery V, Mergler S, Pleyer U (2010) Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 35:751-756
68. Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P, Wendling D, Liote F (2012) Scleritis: a paradoxical effect of etanercept? Etanerceptassociated inflammatory eye disease. J Rheumatol 39:233-239
69. Cobo-Ibanez T, del Carmen OM, Munoz-Fernandez S, Madero-Prado R, Martin-Mola E (2008) Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 47:731-732
70. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM (2011) New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 41:503-510
71. Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87:925
72. Hashkes PJ, Shajrawi I (2003) Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 21:645-646
73. Taban M, Dupps WJ, Mandell B, Perez VL (2006) Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 14:145-150
74. Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G, Teruzzi B, Valcamonica E, Fantini F (2006) Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 58:31-38
75. Monnet D, Moachon L, Dougados M, Brezin AP (2006) Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2:393-397
76. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56:3248-3252
77. Fonollosa A, Artaraz J, Les I, Martinez-Berriotxoa A, Izquierdo JP, Lopez AS, Gardeazaba J, Berasategui B, Martinez-Alday N (2012) Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm 20(1):44-48
78. Seve P, Varron L, Broussolle C, Denis P, Kodjikian L (2012) Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 20:59-60
79. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48:883-886
80. Toussirot E, Pertuiset E (2010) TNFalpha blocking agents and sarcoidosis: an update. Rev Med Interne 31:828-837
81. Massara A, Cavazzini L, La Corte R, Trotta F (2010) Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 39:313-319
82. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F (2009) Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol 5:421-431
83. Bringas Calvo R, Iglesias Cortinas D (2004) Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol 79:357-359
84. Hinkle DM, Dacey MS, Mandelcorn E, Kalyani P, Mauro J, Bates JH, Soukasian SH, Holland GN, Foster CS, Fraunfelder FT, Davis JL, Fraunfelder FW (2012) Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol 31:111-116
85. Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, De Waard PW, Missotten TO, Martinez Ciriano JP, Van Aken E (2009) Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 23:2260-2262
86. Willermain F, Deflorenne C, Bouffioux C, Janssens X, Koch P, Caspers L (2010) Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond) 24:1419
87. Tugal-Tutkun I, Araz B, Taskapili M, Akova YA, Yalniz-Akkaya Z, Berker N, Emre S, Gezer A (2009) Bilateral acute depigmentation of the iris: report of 26 new cases and four-year follow-up of two patients. Ophthalmology 116:1552-1557, 1557. e1
88. Tugal-Tutkun I, Onal S, Garip A, Taskapili M, Kazokoglu H, Kadayifcilar S, Kestelyn P (2011) Bilateral acute iris transillumination. Arch Ophthalmol 129 (10):1312-1319
89. Mazzotti L (1948) Possibility of using the allergic reactions due to the administration of Hetrazan as an auxiliary diagnostic test for onchocerciasis in Mexico. Revista del Instituto de Salubridad y Enfermedades Tropicales 9:235-237 (in Spanish)
90. Francis H, Awadzi K, Ottesen EA (1985) The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg 34:529-536
91. Greene BM, Taylor HR, Brown EJ, Humphrey RL, Lawley TJ (1983) Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes. J Infect Dis 147:890-897
92. Bird AC, El-Sheikh H, Anderson J, Fuglsang H (1980) Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol 64:191-200
93. Taylor HR, Greene BM (1981) Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis. Br J Ophthalmol 65:494-502
94. Taylor HR, Murphy RP, Newland HS, White AT, D'Anna SA, Keyvan-Larijani E, Aziz MA, Cupp EW, Greene BM (1986) Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol 104:863-870
95. Kinshuck D (1991) Glauline (metipranolol) induced uveitis and increase in intraocular pressure. Br J Ophthalmol 75:575
96. Akingbehin T, Villada JR (1991) Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 75:519-523
97. Beck RW, Moke P, Blair RC, Nissenbaum R (1996) Uveitis associated with topical beta-blockers. Arch Ophthalmol 114:1181-1182
98. O'Connor GR (1993) Granulomatous uveitis and metipranolol. Br J Ophthalmol 77:536-538
99. Watanabe TM, Hodes BL (1997) Bilateral anterior uveitis associated with a brand of metipranolol. Arch Ophthalmol 115:421-422
100. Kamalarajah S, Johnston PB (1999) Bilateral anterior uveitis associated with 0.3% minims metipranolol. Eye (Lond) 13(Pt 3a):380-381
101. Melles RB, Wong IG (1994) Metipranolol-associated granulomatous iritis. Am J Ophthalmol 118:712-715
102. Schultz JS, Hoenig JA, Charles H (1993) Possible bilateral anterior uveitis secondary to metipranolol (optipranolol) therapy. Arch Ophthalmol 111:1606-1607
103. Akingbehin T, Villada JR, Walley T (1992) Metipranolol-induced adverse reactions: I. The rechallenge study. Eye (Lond) 6(Pt 3):277-279
104. Martins JC, Wilensky JT, Asseff CF, Obstbaum SA, Buerk KM (1974) Corticosteroid-induced uveitis. Am J Ophthalmol 77:433-437
105. Krupin T, LeBlanc RP, Becker B, Kolker AE, Podos SM (1970) Uveitis in association with topically administered corticosteroid. Am J Ophthalmol 70:883-885
106. Shin DH, Kass MA, Kolker AE, Becker B, Marr JJ, Bell EC (1976) Positive FTAABS tests in subjects with corticosteroid-induced uveitis. Am J Ophthalmol 82:259-260
107. Mindel JS, Goldberg J, Tavitian HO (1979) Similarity of the intraocular pressure response to different corticosteroid esters when compliance is controlled. Ophthalmology 86:99-107
108. Byles DB, Frith P, Salmon JF (2000) Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 130:287-291
109. Becker HI, Walton RC, Diamant JI, Zegans ME (2004) Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 122:1063-1066
110. Nguyen EV, Azar D, Papalkar D, McCluskey P (2008) Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. J Glaucoma 17:40-42
111. Cates CA, Jeffrey MN (2003) Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye (Lond) 17:670-671
112. Goyal R, Ram AR (2000) Brimonidine tartarate 0.2% (Alphagan) associated granulomatous anterior uveitis. Eye (Lond) 14:908-910
113. Velasque L, Ducousso F, Pernod L, Vignal R, Deral V (2004) Anterior uveitis and topical brimonidine: a case report. J Fr Ophtalmol 27:1150-1152
114. Hondeghem K, Augustinus B, De Smet MD (2009) Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports. Bull Soc Belge Ophtalmol 311:51-52
115. Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138-147
116. Alm A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752
117. Gabelt BT, Kaufman PL (1989) Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49:389-402
118. Bito LZ (1997) Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 41(Suppl 2):S1-S14
119. Grierson I, Jonsson M, Cracknell K (2004) Latanoprost and pigmentation. Jpn J Ophthalmol 48:602-612
120. Eakins KE (1977) Prostaglandin and non-prostaglandin mediated breeakdown of the blood-aqueous barrier. Exp Eye Res 25(Suppl):483-498
121. Unger WG (1989) Mediation of the ocular response to injury and irritation: peptides versus prostaglandins. Prog Clin Biol Res 312:293-328
122. Warwar RE, Bullock JD, Ballal D (1998) Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105:263-268
123. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R (1998) Anterior uveitis associated with latanoprost. Am J Ophthalmol 126:37-41
124. Lopilly Park HY, Kim JH, Lee KM, Park CK (2012) Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea. Exp Eye Res 94:13-21
125. Chang JH, McCluskey P, Missotten T, Ferrante P, Jalaludin B, Lightman S (2008) Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol 92:916-921
126. Kirsch LS, Arevalo JF, Chavez De La Paz E, Munguia D, De Clercq E, Freeman WR (1995) Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102:533-542, discussion 42-43
127. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR (2007) Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 23:487-491
128. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
129. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-1398
130. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
131. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041-2049
132. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124-1133, e1
133. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular agerelated macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57-65, e5
134. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594-1602
135. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102-1112, e1
136. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 355:1432-1444
137. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Brown DM (2011) The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trapeye dosed as-needed after 12-week fixed dosing. Ophthalmology 118:1098-1106
138. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X, Beckmann K, Haller JA (2012) Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 119:1024-1032
139. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Ruckert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS (2011) The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 118:1819-1826
140. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248
141. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-583
142. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399-2405
143. Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508, e1-25
144. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham ET Jr, Goldbaum M, Katz B, Guyer D (2008) Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 92:1606-1611
145. Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M (2006) Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 26:841-842
146. Bakri SJ, Larson TA, Edwards AO (2008) Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:779-781
147. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I (2009) Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 29:313-318
148. Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG (2010) Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 30:1432-1440
149. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, Oyagi T, Sawada K (2010) Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 117:512-516.
150. Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H, Ooto S, Sasahara M, Iwama D, Yoshimura N (2010) Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 30:485-490
151. Yenerel NM, Dinc UA, Gorgun E (2008) A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 24:362-363
152. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F (2007) Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 23:240-242
153. Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344-1349
154. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816
155. Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP (2007) Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114:1702-1712
156. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731-1739
157. Antoszyk AN, Tuomi L, Chung CY, Singh A (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862-874
158. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532-1542
159. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81-87
160. Antonopoulos C, Stem M, Comer GM (2011) Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab. Clin Ophthalmol 5:1659-1662
161. Kay CN, Tarantola RM, Gehrs KM, Folk JC, Mahajan VB, Boldt HC, Syed NA, Russell SR (2011) Uveitis following intravitreal bevacizumab: a non-infectious cluster. Ophthalmic Surg Lasers Imaging 42:292-296
162. Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U (2009) Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 93:457-462
163. Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S (2008) Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 115:1911-1915
164. Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA (2011) Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 118:2028-2034
165. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA (2011) Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 152:266-272
166. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831-839
167. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115-1128
168. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127:1101-1114
169. Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115:1447-1449.
170. Wang LC, Yang CM (2005) Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm 13:295-300
171. Moshfeghi DM, Kaiser PK, Bakri SJ, Kaiser RS, Maturi RK, Sears JE, Scott IU, Belmont J, Beer PM, Quiroz-Mercado H, Mieler WF (2005) Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 36:24-29
172. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA (2003) Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121:1279-1282
173. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A (2003) Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23:686-691
174. Ozkiris A, Erkilic K (2005) Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 40:63-68
175. Jonisch J, Lai JC, Deramo VA, Flug AJ, Fastenberg DM (2008) Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br J Ophthalmol 92:1051-1054
176. Simon S, Gray T, Dhanapala M, Gilhotra J (2010) Pseudohypopyon following intravitreal triamcinolone acetonide injection in a phakic eye. Clin Experiment Ophthalmol 38:76-77
177. Sharma MC, Lai WW, Shapiro MJ (2004) Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 23:398-399
178. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA (2004) Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 138:489-492
179. Lam A, Garg SJ, Spirn MJ, Fineman M, Sivalingam A (2008) Sterile endophthalmitis following intravitreal injection of preservative-free triamcinolone acetonide. Retinal Cases and Brief Reports 2:228-230
180. Maia M, Farah ME, Belfort RN, Penha FM, Lima Filho AA, Aggio FB, Jr Belfort R (2007) Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 91:1122-1124
181. Jonas JB, Kreissig I, Spandau UH, Harder B (2006) Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 141:579-580
182. Taban M, Singh RP, Chung JY, Lowder CY, Perez VL, Kaiser PK (2007) Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol 144:50-54
183. Salz D, Prenner J, Cunningham ETJ (2010) Local complications of IV anti-VEGF therapy. Review of Ophthalmology 17:66-75
184. Spratt A, Key T, Vivian AJ (2008) Chronic anterior uveitis following bacille Calmette-Guerin vaccination: molecular mimicry in action? J Pediatr Ophthalmol Strabismus 45:252-253
185. Garip A, Diedrichs-Mohring M, Thurau SR, Deeg CA, Wildner G (2009) Uveitis in a patient treated with Bacille-Calmette-Guerin: possible antigenic mimicry of mycobacterial and retinal antigens. Ophthalmology 116:2457-2462.
186. Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:635-643
187. Pancaldi P, Van Linthoudt D, Alborino D, Haefliger JM, Ott H (1993) Reiter's syndrome after intravesical Bacillus Calmette-Guerin treatment for superficial bladder carcinoma. Br J Rheumatol 32:1096-1098
188. Faus S, Martinez Montauti JM, Puig L (1993) Reiter's syndrome after administration of intravesical bacille Calmette-Guerin. Clin Infect Dis 17:526-527
189. Donaldson RC, Canaan SA Jr, McLean RB, Ackerman LV (1974) Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery 76:771-778
190. Wertheim M, Astbury N (2002) Bilateral uveitis after intravesical BCG immunotherapy for bladder carcinoma. Br J Ophthalmol 86:706
191. Chevrel G, Zech C, Miossec P (1999) Severe uveitis followed by reactive arthritis after bacillus Calmette-Guerin therapy. J Rheumatol 26:1011
192. Price GE (1994) Arthritis and iritis after BCG therapy for bladder cancer. J Rheumatol 21:564-565
193. Missioux D, Hermabessiere J, Sauvezie B (2010) Arthritis and iritis after bacillus Calmette-Guerin therapy. J Rheumatol 1995:22
194. Jacob M, Gambrelle J, Fleury J, Durieu I, Kodjikian L, Duquesne N, Grange JD (2006) Panuveitis following intravesical bacille Calmette-Guerin therapy. J Fr Ophtalmol 29:552-555
195. Hegde V, Dean F (2005) Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guerin (BCG) vaccination. Acta Paediatr 94:635-636
196. Guex-Crosier Y, Chamot L, Zografos L (2003) Chorioretinitis induced by intravesical Bacillus Calmette-Guerin (BCG) instillations for urinary bladder carcinoma. Klin Monbl Augenheilkd 220:193-195
197. Lish A, Berman DH (1993) Tuberculin-triggered panuveitis in a patient recently treated for active pulmonary tuberculosis. Am J Ophthalmol 116:771-773
198. Nussenblatt RB, Palestine AG (1989) Uveitis Fundamentals and Practice. Yearbook Medical Publishers, Chicago
199. Islam SM, El-Sheikh HF, Tabbara KF (2000) Anterior uveitis following combined vaccination for measles, mumps and rubella (MMR): a report of two cases. Acta Ophthalmol Scand 78:590-592
200. Sedaghat M, Zarei-Ghanavati S, Shokoohi S, Ghasemi A (2007) Panuveitis and dermal vasculitis following MMR vaccination. East Mediterr Health J 13:470-474
201. Blumberg S, Bienfang D, Kantrowitz FG (1980) A possible association between influenza vaccination and small-vessel vasculitis. Arch Intern Med 140:847-848
202. Thurairajan G, Hope-Ross MW, Situnayake RD, Murray PI (1997) Polyarthropathy, orbital myositis and posterior scleritis: an unusual adverse reaction to influenza vaccine. Br J Rheumatol 36:120-123
203. Wells MB, Garg S (2009) Bilateral panuveitis after influenza vaccination. Retinal Cases and Brief Reports 3:386-387
204. Blanche P, Decrette C, Sicard D (1994) Development of uveitis following vaccination for influenza. Clin Infect Dis 19:979
205. Knopf HL (1991) Recurrent uveitis after influenza vaccination. Ann Ophthalmol 23:213-214
206. Mendrinos E, Baglivo E (2010) Acute posterior multifocal placoid pigment epitheliopathy following influenza vaccination. Eye (Lond) 24:180-181
207. Rothova A, de Groot JD, Mudrikova T (2011) Reactivation of acute retinal necrosis after flu H1N1 vaccination. Br J Ophthalmol 95:291
208. Brezin AP, Massin-Korobelnik P, Boudin M, Gaudric A, LeHoang P (1995) Acute posterior multifocal placoid pigment epitheliopathy after hepatitis B vaccine. Arch Ophthalmol 113:297-300
209. Fried M, Conen D, Conzelmann M, Steinemann E (1987) Uveitis after hepatitis B vaccination. Lancet 2:631-632
210. Islam SM, Tabbara KF (2002) Causes of uveitis at The Eye Center in Saudi Arabia: a retrospective review. Ophthalmic Epidemiol 9:239-249
211. Fraunfelder FW, Suhler EB, Fraunfelder FT (2010) Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol 29:26-29
212. Esmaeli-Gutstein B, Winkelman JZ (1999) Uveitis associated with varicella virus vaccine. Am J Ophthalmol 127:733-734
213. Lin P, Yoon MK, Chiu CS (2009) Herpes zoster keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination. Ocul Immunol Inflamm 17:33-35
214. Naseri A, Good WV, Cunningham ET Jr (2003) Herpes zoster virus sclerokeratitis and anterior uveitis in a child following varicella vaccination. Am J Ophthalmol 135:415-417
215. Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK (2011) Acute retinal necrosis after herpes zoster vaccination. Arch Ophthalmol 129:1495-1497